Advertisement

Search Results

Advertisement



Your search for ,VIA matches 1431 pages

Showing 51 - 100


WHI Funding Future Unclear

Women’s Health Initiative (WHI) investigators were informed on April 21 that the Department of Health and Human Services (HHS) will terminate WHI Regional Center (RC) contracts at the end of the current fiscal year (September 2025). The WHI Clinical Coordinating Center (CCC) will continue...

hematologic malignancies
lymphoma

Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 CAR T Cells in Relapsed/Refractory Mantle Cell Lymphoma

In a single-center phase I/II study reported in the Journal of Clinical Oncology, Shah et al found that adaptive manufactured lentiviral anti-CD20/anti-CD19 (LV20.19) chimeric antigen receptor (CAR) T-cell treatment was highly active in relapsed or refractory mantle cell lymphoma. Study Details In...

lung cancer

Low-Dose CT Screening for Lung Cancer in a High-Risk Population

In a UK prospective longitudinal cohort study (SUMMIT) reported in The Lancet Oncology, Bhamani et al found that large-scale, low-dose computed tomography (CT) screening for lung cancer is effective and “can be delivered efficiently” in a diverse high-risk population. As stated by the...

Virtual Reality Therapy May Improve Chemotherapy-Associated Side Effects

A study conducted by Stansel et al, which was published in the journal Clinical Journal of Oncology Nursing, highlighted the potential of virtual reality therapy to reduce patient stress, pain, and negative affect during chemotherapy sessions. The findings also appeared to support its delivery and...

gastroesophageal cancer

Neoadjuvant Chemoradiotherapy Plus Immunotherapy in Esophageal Squamous Cell Carcinoma

Neoadjuvant therapy that combines chemotherapy, radiotherapy, and the investigational PD-1 inhibitor sintilimab led to a significantly higher pathologic complete response rate in patients with locally advanced esophageal squamous cell carcinoma, according to data presented at the 2025 ASCO...

integrative oncology

Digital Integrative Medicine Intervention for Patients Undergoing Active Cancer Treatment

Cancer and its treatments often contribute to burdensome symptoms that negatively impact patients’ quality of life and treatment outcomes, including fatigue, anxiety, and depression.1 Many patients experience multiple symptoms concurrently2 that can disrupt their treatments and lead to unplanned...

colorectal cancer
pancreatic cancer
gastrointestinal cancer

Overcoming Resistance to KRAS G12C Inhibitors in Pancreatic and Colorectal Cancers

A study evaluating the genetic landscape of candidate primary resistance alterations relevant to KRAS targeting in KRAS G12C–mutant colorectal cancers and pancreatic ductal adenocarcinomas (PDAC) has found that putative resistance alterations are prevalent in these cancers. The finding may explain...

The Death of Alexei Navalny and the Discovery of Cancer Chemotherapy

Remembering  Alexi Anatolyevich Navalny: The Russian opposition leader, lawyer, anticorruption activist, and political prisoner, Alexi Navalny died in the Arctic Wolf prison in Siberia approximately 1 year ago on February 16, 2024.  He was designated a Prisoner of Conscience by Amnesty...

supportive care
immunotherapy
symptom management
issues in oncology

Text Message Platform May to Help Address ‘Time Toxicity’ in Patients With Cancer

Digital technology may help to safely reduce the amount of time some patients with cancer spend receiving care—also referred to as “time toxicity”—according to a recent study published by Bange et al in NEJM Catalyst. Background Patients with cancer often spend a large amount of time on activities...

geriatric oncology

Influencing Geriatric Oncology Practice Worldwide: 2024 International Society of Geriatric Oncology Conference

The Annual Meeting of the International Society of Geriatric Oncology (SIOG) was held from October 17–19, 2024, in Montreal. The conference theme was “Promoting Equity and Enhancing Optimal Care Delivery.” The conference chairs were Shabbir Alibhai, MD, MSc, FRCPC, and Martine Puts, RN, PhD, FAAN,...

palliative care
lung cancer

How Telehealth Is Broadening Access to Early Palliative Care and Improving Outcomes for Patients With Advanced Lung Cancer

Although national guidelines, including ASCO’s palliative care guideline,1 call for the early integration of palliative and oncology care for patients with advanced cancer, only 36% of those with a very poor prognosis and 18% of those with a poor prognosis receive palliative care services.2 The...

gynecologic cancers
issues in oncology

Short- vs Standard-Course Radiation Therapy for Endometrial Cancer

Short-course, higher-dose vaginal brachytherapy for endometrial cancer may demonstrate comparable efficacy to more frequent, lower-dose sessions, according to a recent study published by Suneja et al in JCO Oncology Advances. Background Endometrial cancer is the most common cancer type of the...

multiple myeloma
myelodysplastic syndromes
leukemia

In Case You Missed It: Additional Studies of Interest From ASH 2024

A record-breaking number of abstracts were submitted for the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, and nearly 8,000 were accepted. The ASCO Post strives to provide in-depth coverage of those with the greatest impact. Here, we offer snapshots of others of...

hematologic malignancies
supportive care

Fecal Microbiota Transplantation Following ASCT

Oral fecal microbiota transplantation may be a feasible and safe option to prevent graft-vs-host disease in patients with hematologic malignancies undergoing allogeneic stem cell transplant (ASCT), according to a recent report published by Reddi et al in Nature Communications. The findings built on ...

2.83% Medicare Physician Reimbursement Cut Finalized for 2025; Estimated 4% Cut for Medical Oncology

Late in 2024, the Centers for Medicare & Medicaid Services (CMS) issued the 2025 Physician Fee Schedule (PFS) final rule adopting changes for Medicare payments under the PFS. CMS also released the 2025 Hospital Outpatient Prospective Payment System final rule, which sets hospital outpatient...

integrative oncology

Exercise Therapy as Candidate Anticancer Strategy

Guest Editor’s Note: With growing evidence indicating that regular physical activity helps control cancer symptoms, oncology guidelines recommend exercise before, during, and after cancer treatment. Observational data also demonstrate a promising association between physical activity and favorable...

skin cancer
immunotherapy

Novel Combination Regimen May Prevent Squamous Cell Carcinoma

A recent study by Demehri et al of Mass General Brigham investigates whether calcipotriol—a vitamin D analog—plus fluorouracil may prevent squamous cell carcinoma (SCC), with benefits lasting 5 years after treatment. This combination therapy is the first to activate specific components of the...

hematologic malignancies

Studies Point to the Role of Diet in Hematologic Malignancies

According to research reported at the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, a link seems to exist between hematologic malignancies and dietary components. The speakers said their studies may ultimately lead to dietary interventions that could alter the course of ...

immunotherapy

Mesenchymal Cell Therapy Approved for Steroid-Refractory Acute GVHD

The U.S. Food and Drug Administration (FDA) recently approved remestemcel-L-rknd (Ryoncil), an allogeneic bone marrow–derived mesenchymal stromal cell therapy for steroid-refractory acute graft-vs-host disease (GVHD) in pediatric patients 2 months of age and older. The application received Orphan...

breast cancer

Anthracyclines Plus Taxane-Based Chemotherapy for Certain Patients at High Risk for Breast Cancer Recurrence

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2-negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline plus taxane-based chemotherapy regimens compared with those...

lymphoma

Maayan Levy, PhD, and Marco Ruella, MD, on How a Ketogenic Diet Enhances CAR T-Cell Antitumor Function Via Beta-Hydroxybutyrate (BHB)

Maayan Levy, PhD, and Marco Ruella, MD, of the University of Pennsylvania, Perelman School of Medicine, discuss findings on whether ketogenic diet-derived BHB can be provided as a dietary intervention to augment CAR-T function in multiple cancer models. The results of this study will be translated...

issues in oncology

Impact of Prevention and Screening on Mortality From Five Common Cancers

Improvements in cancer prevention and screening have averted more deaths from five cancer types combined over the past 45 years than treatment advances, according to a modeling study led by researchers at the National Institutes of Health (NIH). The study, published by Goddard et al in JAMA...

colorectal cancer

Onvansertib With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer

In a phase II trial reported in the Journal of Clinical Oncology, Ahn et al found the combination of the PLK1 inhibitor onvansertib with FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus bevacizumab showed activity in the second-line treatment of KRAS-mutant metastatic colorectal cancer....

lung cancer

Highlights From the 2024 World Conference on Lung Cancer

At the 2024 World Conference on Lung Cancer (WCLC), more than 7,000 clinicians and scientists gathered in San Diego in celebration of the 50th anniversary of the International Association for the Study of Lung Cancer (IASLC). In this supplement to The ASCO Post, we review impactful abstracts from...

integrative oncology
symptom management

Participation in Virtual Prehabilitation and Outcomes Following Thoracic Cancer Surgery

Guest Editor’s Note: Oncology guidelines recommend prehabilitation exercises to minimize postoperative complications. However, the COVID-19 pandemic imposed severe restrictions on patient access to in-person exercise programs offered by hospitals and clinics. In this article, Dr. Krupali Desai...

breast cancer

Breast Cancer in 2024: Looking Back and Moving Forward

In a recent issue of The New York Times, Barron Lerner discussed Betty Ford’s breast cancer diagnosis in 1974.1 He described the state of the art of breast cancer treatment at the time and how her diagnosis accelerated the uptake of screening across the country. But her cancer was not...

cardio-oncology
immunotherapy

When Cancer and Cardiovascular Disease Intersect

The annual Global Cardio-Oncology Summit (GCOS) was held September 22 to 24 in Minneapolis, with 430 health-care professionals attending from 20 countries. The Summit brings together health-care professionals from diverse disciplines including members of the International Cardio-Oncology...

survivorship
issues in oncology
solid tumors

Large Proportion of Childhood Cancer Survivors May Experience Significant Fear of Cancer Recurrence

Investigators have found that one-third of adult survivors of childhood cancers may experience a severe fear of cancer recurrence that impacts their daily lives, according to a recent study published by Pizzo et al in JAMA Network Open. Background Although the number of survivors of childhood...

hepatobiliary cancer
issues in oncology

Higher Dosage of Radioembolization With Y-90 Therapy May Improve Survival Rates and Facilitate Curative Treatment in Patients With Hepatocellular Carcinoma

Researchers found that a higher dosage of radioembolization treatment using yttrium (Y)-90 microspheres than previously recommended may benefit patients with hepatocellular carcinoma, according to a recent study published by Chen et al in Liver Cancer. The findings could be practice-changing....

genomics/genetics

Two U.S. Scientists Named Recipients of the 2024 Nobel Prize in Physiology or Medicine

The 2024 Nobel Prize in Physiology or Medicine has been awarded jointly to two U.S. scientists: Victor Ambros, PhD, and Gary Ruvkun, PhD, for the discovery of microRNA and its role in post-transcriptional gene regulation. The recipients were named in a news release issued by The Nobel Assembly at ...

prostate cancer
issues in oncology

Intensity-Modulated Radiation Therapy and Proton-Beam Therapy May Offer Equally High Quality of Life and Tumor Control in Patients With Localized Prostate Cancer

Two types of contemporary radiation therapy—proton-beam therapy or intensity-modulated radiation therapy—may provide comparable rates of tumor control with no differences in patient-reported quality of life among patients with low- and intermediate-risk prostate cancer, according to new findings...

issues in oncology
cost of care

More Than Half of AYA Cancer Survivors Experience Financial Toxicity and Are Unable to Afford Food and Housing

A study conducted by Kaitlyn Lapen, MD, a radiation oncologist resident at Memorial Sloan Kettering Cancer Center, and colleagues evaluated the financial challenges adolescent and young adults (AYA) survivors experience during and after treatment. They found that more than half (54%) of these...

gynecologic cancers

Tisotumab Vedotin-tftv for Recurrent or Metastatic Cervical Cancer

On April 29, 2024, tisotumab vedotin-tftv (Tivdak) was granted regular approval for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.1 Tisotumab vedotin is a tissue factor–directed antibody and microtubule inhibitor conjugate. The agent was granted...

hepatobiliary cancer

LEAP-012: Pembrolizumab Plus Lenvatinib Added to TACE Improved Progression-Free Survival in HCC

According to results of the first interim analysis of the phase III LEAP-012 trial, the anti–PD-1 therapy pembrolizumab plus the tyrosine kinase inhibitor lenvatinib, in combination with transarterial chemoembolization (TACE), significantly improved progression-free survival compared with TACE...

immunotherapy
issues in oncology

Can AI Tool Improve Detection of Immune-Related Adverse Events in Patients With Cancer?

Researchers have explored whether an artificial intelligence (AI)-based tool could help to detect immune-related adverse events in patients with cancer, according to a recent study published by Sun et al in the Journal of Clinical Oncology. Background Although immune checkpoint inhibitors can...

solid tumors

Fam-Trastuzumab Deruxtecan-nxki in Unresectable or Metastatic HER2-Positive Solid Tumors

On April 5, 2024, fam-trastuzumab deruxtecan-nxki (T-DXd) was granted accelerated approval for adults with unresectable or metastatic HER2-positive (immunohistochemistry 3+) solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.1 Supporting...

global cancer care

Prescription for Progress: Lancet Oncology Commission’s Practical Strategies for Global Cancer Surgery

In certain regions of the world, cancer claims more lives than HIV, tuberculosis, and malaria combined, yet surgery has been relegated to the sidelines of global health initiatives. This critical need to address global inequities in access to safe, timely, and affordable cancer surgery led to the...

supportive care
symptom management

Role of Patient-Reported Outcome Measures in Assessing Chemotherapy-Induced Peripheral Neuropathy

A cohort study reported in JAMA Network Open by Li et al demonstrated the superiority of patient-reported outcome measures vs other methods in assessing nerve damage in patients with cancer who underwent neurotoxic chemotherapy. “Accordingly, the adoption of chemotherapy-induced peripheral...

cardio-oncology

An Integrated Approach to Treating Cancer and Cardiovascular Disease: When Oncologists and Cardiologists Collaborate

At the 2024 Debates and Didactics in Hematology and Oncology Conference, sponsored by Emory’s Winship Cancer Institute, cardiologist-by-training Anant Mandawat, MD, FACC, briefly reviewed how the emerging field of cardio-oncology is blazing a path toward “bigger and bolder cancer care” and offered...

gynecologic cancers
geriatric oncology

Age Is Just a Number: Treatment Considerations for Endometrial Cancer in Older Women

Endometrial cancer is most frequently diagnosed among women aged 55 to 65, with a median age at diagnosis of 64 years.1 In epidemiologic studies, women diagnosed with endometrial cancer at an older age are more likely to have high-grade disease, aggressive histology, deep myometrial invasion, lower ...

gynecologic cancers

Efficacy of ‘Symptom-Triggered Testing’ for Detection of Ovarian Cancer

“Symptom-triggered testing”—prompted by symptoms such as pain, abdominal bloating/swelling, and feeling full soon after starting to eat—detected early-stage aggressive ovarian cancer in one of four individuals affected, according to an analysis from the ROCkeTS trial published by Kwong et al in the ...

gynecologic cancers
issues in oncology

Salpingectomy vs Tubal Occlusion

Women whose fallopian tubes are removed during sterilization via laparoscopy may have only marginally more surgical complications compared with those whose tubes are cut during tubal occlusion, according to a recent study published by Strandell et al in The Lancet Regional Health–Europe. The...

leukemia

Ponatinib and Blinatumomab in Newly Diagnosed Ph-Positive ALL

In an updated analysis of a single-center phase II trial reported in the Journal of Clinical Oncology, Hagop Kantarjian, MD, and colleagues found that the simultaneous combination of ponatinib and blinatumomab continued to be associated with good outcomes in newly diagnosed patients with...

breast cancer
cardio-oncology

Heart-Sparing Radiation Therapy Technique in Left-Sided Breast Cancer: Benefits and Costs

A model-based analysis reported in JACC: CardioOncology by Busschaert et al suggested that the heart-sparing deep inspiration breath-hold vs free-breathing radiation therapy technique is cost-effective—despite increasing treatment time—and may improve the long-term cardiovascular health of patients ...

gastroesophageal cancer
hepatobiliary cancer
immunotherapy
issues in oncology

Fecal Microbiota Transplant May Help Patients With Gastrointestinal Cancers Overcome Immunotherapy Resistance

Fecal microbiota transplants may improve the effectiveness of immunotherapy in patients with gastrointestinal cancers, according to a recent study published by Kim et al in Cell Host & Microbe. Background Although immune checkpoint inhibitors have revolutionized cancer treatment, many patients...

breast cancer
supportive care

Update on Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial in Patients With Breast Cancer

Guest Editor’s Note: Chemotherapy and its side effects can lead to decreased physical activity and poor diet quality, resulting in unfavorable changes in physical functioning and quality of life. However, adopting healthy behaviors during cancer treatments can be challenging because of physical,...

issues in oncology
hematologic malignancies
leukemia
lymphoma
bladder cancer

Cancer Risk From Exposure to Pesticides May Be Comparable to Risk From Smoking, Study Finds

Agricultural pesticides may carry a similar risk as smoking for some types of cancers, according to a recent study published by Gerken et al in Frontiers in Cancer Control and Society.   Background In modern agriculture practices, pesticides are essential to ensure high enough crop yields and food...

Introducing ‘Conexiant’

The publisher and editorial staff of The ASCO Post are happy to share an exciting announcement. While our company was formerly known as Harborside, powered by BroadcastMed, earlier this summer we announced a new name and platform for our business, Conexiant. Importantly, we continue our essential...

prostate cancer
issues in oncology

Liquid Biopsy May Enable Monitoring of Disease Evolution in Patients With Metastatic Prostate Cancer

DNA/RNA material contained in circulating extracellular vesicles secreted into the blood stream by tumor cells may capture cancer genomics and transcriptomic evolution in patients with metastatic prostate cancer, according to a recent study published by Casanova et al in Cancer Cell. Background...

prostate cancer

MAST Trial: Metformin Does Not Slow Disease Progression of Low-Risk Prostate Cancer

The hypoglycemic agent metformin failed to slow disease progression in men with low-risk localized prostate cancer undergoing active surveillance, according to the results of the randomized, controlled MAST trial reported at the 2024 ASCO Annual Meeting.1 In addition, the use of metformin was...

Advertisement

Advertisement




Advertisement